To date, benign diseases of the male and female lower urinary and genital tract, such as erectile dysfunction, bladder overactivity, lower urinary tract symptomatology secondary to benign prostatic ...

A research-driven evaluation assessing the comparative effectiveness of phosphodiesterase type 5 (PDE5) inhibitors is contributing to ongoing clinical discourse around vascular-mediated functional ...

Erectile dysfunction drugs were associated with reduced risk of Alzheimer's disease, electronic health record (EHR) data from 270,000 men in the U.K. suggested. Over a median follow-up of about 5 ...

Men taking phosphodiesterase type 5 (PDE5) inhibitors for erectile dysfunction (ED) have lower risks of overall MACE, cardiovascular mortality, and all-cause mortality than those not on these ...

CHICAGO -- The two most popular medications for erectile dysfunction (ED) may confer substantial cardiovascular benefits for men with ED and concurrent heart disease, according to an analysis of a ...

CORVALLIS, Ore., May 8, 2025 /PRNewswire/ -- Karma Biosciences announced today that it has applied for patent protection for two new drug formulations utilizing its proprietary excipient Zenergy™ .

For men with a history of myocardial infarction or PCI, it may be risky to use nitrates for angina and phosphodiesterase-5 (PDE5) inhibitors for erectile dysfunction at the same time, a large Swedish ...

Urologic surgeon Jose M. Flores, MD is lead author of a new study investigating the risk of biochemical recurrence after radical prostatectomy when taking ED drugs. There have been conflicting studies ...

Please provide your email address to receive an email when new articles are posted on . Men with CAD who combined nitrates with common ED drugs were at higher risk for death and adverse CV events. The ...